Smart spacer could help kids breathe easier

NCT ID NCT07500246

Recruiting now Disease control Sponsor: Luxembourg Institute of Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new digital spacer (Whizz) helps children aged 5-16 with asthma use their inhaler correctly and stick to their medication, compared to a standard spacer. Researchers will also look for biomarkers in blood and breath to improve diagnosis and understand how environment affects asthma. The goal is to improve asthma control and quality of life for kids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inhaled corticosteroids (via spacer device)
What this could lead to: If successful, this could show that a digital spacer helps children use their inhaler correctly and stick to their medication, leading to better asthma control.
What could go wrong: This is a relatively small, early-stage trial focused on device usability and adherence, not a new drug. Results may not apply to all children or guarantee long-term improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease asthma childhood onset asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA ASTHMA CHILDHOOD INHALATION SPACERS

Contacts and locations

Locations

Luxembourg Research Clinic (LRC)
RECRUITING

Luxembourg, Luxembourg

More trials for these conditions

Other studies related to the condition(s) this trial covers.